Top Growth Companies With Insider Ownership January 2025

As global markets continue to react positively to the Trump administration's emerging policies, with U.S. stocks reaching record highs and growth stocks outperforming value shares, investors are increasingly focused on companies that demonstrate robust growth potential and strong insider ownership. In such a dynamic environment, firms where insiders hold significant stakes can signal confidence in the company's future prospects, making them attractive considerations for those seeking growth opportunities in an evolving market landscape.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)	17.3%	20.5%
Seojin SystemLtd (KOSDAQ:A178320)	32.1%	39.9%
SKS Technologies Group (ASX:SKS)	29.7%	24.8%
Propel Holdings (TSX:PRL)	36.5%	38.9%
On Holding (NYSE:ONON)	19.1%	29.7%
Pharma Mar (BME:PHM)	11.9%	55.1%
Kingstone Companies (NasdaqCM:KINS)	20.8%	24.9%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	135%
Elliptic Laboratories (OB:ELABS)	26.8%	121.1%
Fulin Precision (SZSE:300432)	13.6%	71%

Click here to see the full list of 1477 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Genomictree (KOSDAQ:A228760)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Genomictree Inc. is a biomarker-based molecular diagnostics company that develops and commercializes products for detecting cancer and infectious diseases, with a market cap of approximately ₩463.01 billion.

Operations: The company's revenue is primarily derived from its Cancer Molecular Diagnosis Business, which generated ₩2.06 billion, and its Genomic Analysis and Other Business, contributing ₩144 million.

Insider Ownership: 16.1%

Earnings Growth Forecast: 115.9% p.a.

Genomictree is trading at 68.5% below its estimated fair value, suggesting potential undervaluation. Despite having a highly volatile share price recently, the company is expected to become profitable in the next three years with earnings forecasted to grow significantly at 115.9% annually. However, it currently lacks meaningful revenue (₩2 billion) and its Return on Equity is projected to remain low at 5.7%. No substantial insider trading activity has been reported over the past three months.

• Click to explore a detailed breakdown of our findings in Genomictree's earnings growth report.
• Our valuation report unveils the possibility Genomictree's shares may be trading at a premium.

Akatsuki (TSE:3932)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Akatsuki Inc. operates in the gaming, comic, and related industries primarily in Japan, with a market cap of ¥42.83 billion.

Operations: The company generates revenue from its segments, with ¥23.07 billion from games and ¥1.03 billion from comics.

Insider Ownership: 29.4%

Earnings Growth Forecast: 42.4% p.a.

Akatsuki is trading at 55% below its estimated fair value, indicating potential undervaluation. Earnings are projected to grow significantly at 42.36% annually, outpacing the JP market's growth rate of 8.2%. However, revenue growth is slower than ideal at 14.4% per year and Return on Equity is expected to be low at 10.6%. Despite past shareholder dilution, no substantial insider trading activity has been reported recently.

• Take a closer look at Akatsuki's potential here in our earnings growth report.
• The analysis detailed in our Akatsuki valuation report hints at an deflated share price compared to its estimated value.

Formycon (XTRA:FYB)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Formycon AG is a biotechnology company focused on developing biosimilar drugs in Germany and Switzerland, with a market cap of €932.28 million.

Operations: The company generates revenue from its Drug Delivery Systems segment, amounting to €60.80 million.

Insider Ownership: 14.2%

Earnings Growth Forecast: 22.6% p.a.

Formycon AG is experiencing robust growth, with earnings anticipated to increase by 22.6% annually, surpassing the German market's average. Recent EU and UK approvals for its biosimilars FYB203 and FYB202 enhance its revenue prospects, forecasted to grow at 24.6% per year. Despite a low future Return on Equity of 13.4%, Formycon trades at a favorable Price-To-Earnings ratio of 15.1x compared to the German market's 16.6x, indicating potential undervaluation.

• Click here to discover the nuances of Formycon with our detailed analytical future growth report.
• According our valuation report, there's an indication that Formycon's share price might be on the cheaper side.

Make It Happen

• Unlock more gems! Our Fast Growing Companies With High Insider Ownership screener has unearthed 1474 more companies for you to explore.Click here to unveil our expertly curated list of 1477 Fast Growing Companies With High Insider Ownership.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com